Vandetanib -- Re-assessment of Benefit According to §35a, Paragraph 5b, Social Code Book V [Internet].

The aim of this report is to assess the added benefit of vandetanib compared to best supportive care (BSC) as appropriate comparator therapy (ACT) in patients with aggressive and symptomatic medullary thyroid carcinoma (MTC) with unresectable, locally advanced or metastatic disease.

http://ift.tt/2t20Sb9